Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Los Angeles, California 90033


Purpose:

This randomized phase IV trial studies how well the continuous infusion of ropivacaine hydrochloride works in reducing pain after surgery in patients with bladder cancer. Ropivacaine hydrochloride is an anesthetic drug used to decrease pain by numbing an area of the body without putting the patient to sleep. Continuous infusion of ropivacaine hydrochloride may reduce pain and improve the quality of life for patients after bladder surgery.


Study summary:

PRIMARY OBJECTIVES: I. To determine if continuous infusion of local anesthesia (CILA) decreases post-operative pain after radical cystectomy (RC). II. To determine if CILA reduces narcotic requirements after RC. SECONDARY OBJECTIVES: I. To determine if CILA decreases length-of-stay after RC. II. To determine if CILA improves patients satisfaction with post-operative pain control after RC. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive ropivacaine hydrochloride intravenously (IV) continuously over 72 hours after radical cystectomy. ARM II: Patients receive normal saline (placebo) IV continuously over 72 hours after radical cystectomy. After completion of study, patients are followed up within 30 days.


Criteria:

Inclusion Criteria: - Undergoing elective open radical cystectomy - Ability to understand and the willingness to sign a written informed consent Exclusion Criteria: - Allergy or adverse reaction to ropivacaine (ropivacaine hydrochloride) or any amide type of local anesthesia - Allergy or adverse reaction to local anesthesia catheter - Additional surgery at the same time as RC (e.g. nephroureterectomy) - Coagulopathy - Thrombocytopenia - Local or systemic infection - Pregnancy - Chronic hepatic disease - Use of type III antiarrhythmics (e.g. amiodarone) - History of chronic pain and/or daily opioid use


NCT ID:

NCT02438852


Primary Contact:

Principal Investigator
Siamak Daneshmand
University of Southern California


Backup Contact:

N/A


Location Contact:

Los Angeles, California 90033
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.